DK1345937T3 - Quinuclidincarbamatderivater og deres anvendelse som M3-antagonister - Google Patents

Quinuclidincarbamatderivater og deres anvendelse som M3-antagonister

Info

Publication number
DK1345937T3
DK1345937T3 DK01989610T DK01989610T DK1345937T3 DK 1345937 T3 DK1345937 T3 DK 1345937T3 DK 01989610 T DK01989610 T DK 01989610T DK 01989610 T DK01989610 T DK 01989610T DK 1345937 T3 DK1345937 T3 DK 1345937T3
Authority
DK
Denmark
Prior art keywords
antagonists
carbamate derivatives
quinuclidine carbamate
quinuclidine
derivatives
Prior art date
Application number
DK01989610T
Other languages
Danish (da)
English (en)
Inventor
Albero Maria Antonia Buil
Forner Maria Dolors Fernandez
Quinones Maria Prat
Original Assignee
Almirall Prodesfarma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall Prodesfarma Ag filed Critical Almirall Prodesfarma Ag
Application granted granted Critical
Publication of DK1345937T3 publication Critical patent/DK1345937T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK01989610T 2000-12-22 2001-12-20 Quinuclidincarbamatderivater og deres anvendelse som M3-antagonister DK1345937T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200003084 2000-12-22

Publications (1)

Publication Number Publication Date
DK1345937T3 true DK1345937T3 (da) 2006-01-16

Family

ID=8496114

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01989610T DK1345937T3 (da) 2000-12-22 2001-12-20 Quinuclidincarbamatderivater og deres anvendelse som M3-antagonister

Country Status (33)

Country Link
US (3) US7208501B2 (et)
EP (1) EP1345937B1 (et)
JP (1) JP4445704B2 (et)
KR (1) KR100869722B1 (et)
CN (1) CN1298717C (et)
AR (1) AR035410A1 (et)
AT (1) ATE305468T1 (et)
AU (1) AU2002228015B2 (et)
BG (1) BG107930A (et)
BR (1) BR0116450A (et)
CA (1) CA2441896A1 (et)
CZ (1) CZ301323B6 (et)
DE (1) DE60113719T2 (et)
DK (1) DK1345937T3 (et)
EC (1) ECSP034660A (et)
EE (1) EE200300295A (et)
ES (1) ES2248409T3 (et)
HK (1) HK1055120A1 (et)
HU (1) HUP0303529A3 (et)
IL (1) IL156499A0 (et)
MX (1) MXPA03005583A (et)
MY (1) MY136674A (et)
NO (1) NO328707B1 (et)
NZ (1) NZ526580A (et)
PE (1) PE20020719A1 (et)
PL (1) PL362989A1 (et)
RU (1) RU2296762C2 (et)
SI (1) SI1345937T1 (et)
SK (1) SK8002003A3 (et)
UA (1) UA76131C2 (et)
UY (1) UY27092A1 (et)
WO (1) WO2002051841A1 (et)
ZA (1) ZA200304769B (et)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
ATE260277T1 (de) * 2000-06-27 2004-03-15 S A L V A T Lab Sa Von arylalkylaminen abgeleitete carbamate
SK8002003A3 (en) 2000-12-22 2004-05-04 Almirall Prodesfarma Ag Quinuclidine carbamate derivatives and their use as M3 antagonists
AU2002238471B2 (en) 2000-12-28 2007-06-28 Almirall, S.A. Quinuclidine derivatives and their use as M3 antagonists
PL374384A1 (en) 2001-12-14 2005-10-17 Targacept, Inc. Methods and compositions for treatment of central nervous system disorders
MXPA04006206A (es) * 2001-12-20 2004-12-06 S A L V A T Lab Sa Derivados de 1-alquil-azoniabiciclo(2.2.2(octano carbamato y su uso como antagonistas del receptor musrcarinico.
ES2203327B1 (es) * 2002-06-21 2005-06-16 Almirall Prodesfarma, S.A. Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
ES2204295B1 (es) * 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
EP1546099B1 (en) 2002-07-08 2008-12-31 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo 3.1.0 hexane derivatives useful as muscarinic receptor antagonists
TWI295669B (en) 2002-10-30 2008-04-11 Theravance Inc Substituted 4-amino-1-(pyridylmethyl) piperidine and related compounds
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
WO2004089898A1 (en) 2003-04-09 2004-10-21 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
BRPI0409302A (pt) 2003-04-11 2006-04-11 Ranbaxy Lab Ltd derivados azabiciclo como antagonistas de recetores muscarìnicos, método para sua preparação e composição farmacêutica contendo os mesmos
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
US7358244B2 (en) 2003-05-28 2008-04-15 Theravance, Inc. Azabicycloalkane compounds
WO2005007645A1 (en) 2003-07-11 2005-01-27 Theravance, Inc. Substituted 4-amino-1-benzylpiperidine compounds
ATE435855T1 (de) 2003-11-21 2009-07-15 Theravance Inc Verbindungen mit agonistischer wirkung am beta2- adrenergen rezeptor und am muscarinischen rezeptor
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
US7501442B2 (en) 2004-03-11 2009-03-10 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
US7262205B2 (en) 2004-03-11 2007-08-28 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
US7456199B2 (en) 2004-03-11 2008-11-25 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
US7524962B2 (en) 2004-03-11 2009-04-28 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
US7560469B2 (en) 2004-03-11 2009-07-14 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
JP2007528412A (ja) 2004-03-11 2007-10-11 セラヴァンス， インコーポレーテッド ムスカリンレセプターアンタゴニストとして有用なビフェニル化合物
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
TW200538095A (en) 2004-03-11 2005-12-01 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
ES2246170B1 (es) * 2004-07-29 2007-04-01 Almirall Prodesfarma, S.A. Nuevo procedimiento para preparar derivados de carbamato de quinuclidinio.
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
TW200714587A (en) 2005-03-10 2007-04-16 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
WO2006099032A1 (en) 2005-03-10 2006-09-21 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
US7479562B2 (en) 2005-03-10 2009-01-20 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
WO2006099167A1 (en) 2005-03-10 2006-09-21 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
US7659403B2 (en) 2005-03-10 2010-02-09 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7728144B2 (en) 2005-06-13 2010-06-01 Theravance, Inc Biphenyl compounds useful as muscarinic receptor antagonists
DE602006017235D1 (de) 2005-08-22 2010-11-11 Targacept Inc Heteroarylsubstituierte diazatricycloalkane, verfahren zu deren herstellung und deren anwendung
JP5006330B2 (ja) 2005-10-21 2012-08-22 ノバルティス アーゲー Ｉｌ１３に対するヒト抗体および治療的使用
EP1968980A1 (en) * 2005-12-30 2008-09-17 Ranbaxy Laboratories, Ltd. Muscarinic receptor antagonists
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
GB0602778D0 (en) 2006-02-10 2006-03-22 Glaxo Group Ltd Novel compound
AR060607A1 (es) 2006-04-21 2008-07-02 Novartis Ag Derivados de purina,composiciones farmaceuticas que los contienen, metodo de preparacion y usos en enfermedades obstructivas o inflamatorias de las vias respiratorias.
ES2298049B1 (es) 2006-07-21 2009-10-20 Laboratorios Almirall S.A. Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
EP1882691A1 (en) * 2006-07-26 2008-01-30 CHIESI FARMACEUTICI S.p.A. Quinuclidine derivatives as M3 antagonists
US20090286779A1 (en) 2006-09-29 2009-11-19 Novartis Ag Pyrazolopyrimidines as lipid kinase inhibitors
TW200825084A (en) * 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
ATE493174T1 (de) 2007-01-10 2011-01-15 Irm Llc Verbindungen und zusammensetzungen als kanal- aktivierende proteasehemmer
US8367696B2 (en) 2007-02-09 2013-02-05 Astellas Pharma Inc. Aza-bridged-ring compound
US20090010923A1 (en) * 2007-04-24 2009-01-08 University Of Maryland, Baltimore Treatment of cancer with anti-muscarinic receptor agents
ES2361595T3 (es) 2007-05-07 2011-06-20 Novartis Ag Compuestos orgánicos.
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
US8114891B2 (en) 2007-10-01 2012-02-14 Comentis, Inc. 4-substituted quinuclidine derivatives, methods of production, pharmaceutical uses thereof
EP2065385A1 (en) * 2007-11-28 2009-06-03 Laboratorios SALVAT, S.A. Stable crystalline salt of (R)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabiciyclo [2.2.2]oct-3-yl ester
CN101939054B (zh) 2007-12-10 2014-10-29 诺华股份有限公司 有机化合物
BRPI0906838A2 (pt) 2008-01-11 2015-07-14 Novartis Ag Pirimidinas como inibidores de quinase
EP2080507A1 (en) * 2008-01-15 2009-07-22 CHIESI FARMACEUTICI S.p.A. Pharmaceutical formulations comprising an anticholinergic drug
NZ587312A (en) 2008-02-13 2011-12-22 Targacept Inc Combination of alpha 7 nicotinic agonists and antipsychotics
EP2257172A4 (en) * 2008-02-26 2013-07-03 Elevation Pharmaceuticals Inc METHOD AND SYSTEM FOR TREATING CHRONIC OBSTRUCTIVE BRONCHOPNEUMOPATHY USING ANTICHOLINERGIC DELIVERY USING NEBULIZATION
US20100055045A1 (en) 2008-02-26 2010-03-04 William Gerhart Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
KR20110040818A (ko) 2008-06-10 2011-04-20 노파르티스 아게 상피 나트륨 채널 차단제로서의 피라진 유도체
EP2154136A1 (en) 2008-08-08 2010-02-17 CHIESI FARMACEUTICI S.p.A. Quinuclidine carbonate derivatives and medicinal compositions thereof
WO2010045633A2 (en) * 2008-10-17 2010-04-22 National Jewish Health Measurement and analysis of leukotrienes
EP2206712A1 (en) 2008-12-23 2010-07-14 CHIESI FARMACEUTICI S.p.A. "Alkaloid aminoester derivatives and medicinal composition thereof"
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
US20110281917A1 (en) 2009-01-29 2011-11-17 Darrin Stuart Substituted Benzimidazoles for the Treatment of Astrocytomas
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EA201200260A1 (ru) 2009-08-12 2012-09-28 Новартис Аг Гетероциклические гидразоны и их применение для лечения рака и воспаления
GEP201706639B (en) 2009-08-17 2017-03-27 Intellikine Llc Heterocyclic compounds and uses thereof
IN2012DN01453A (et) 2009-08-20 2015-06-05 Novartis Ag
CN102665715A (zh) 2009-10-22 2012-09-12 沃泰克斯药物股份有限公司 治疗囊性纤维化和其他慢性疾病的组合物
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
CA2803433A1 (en) 2010-06-22 2011-12-29 Chiesi Farmaceutici S.P.A. Alkaloid aminoester derivatives and medicinal composition thereof
KR20130111968A (ko) * 2010-06-22 2013-10-11 키에시 파르마슈티시 엣스. 피. 에이. 알칼로이드 아미노에스테르 유도체 및 이의 의약 조성물
BR112012032330A2 (pt) 2010-06-22 2016-11-08 Chiesi Farma Spa formulação em pó seco inalável, uso de uma formulação em pó seco, inalador de pó seco e embalagem
WO2011161018A1 (en) 2010-06-22 2011-12-29 Chiesi Farmaceutici S.P.A. Alkaloid aminoester derivatives and medicinal compositions thereof
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
CA2820600A1 (en) 2010-11-26 2012-05-31 Chiesi Farmaceutici S.P.A. Glycine derivatives and their use as muscarinic receptor antagonists
KR101928505B1 (ko) * 2011-01-28 2018-12-12 에스케이바이오팜 주식회사 피리돈 유도체 및 이를 포함하는 약학적 조성물
EP2673277A1 (en) 2011-02-10 2013-12-18 Novartis AG [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
US20120220557A1 (en) 2011-02-17 2012-08-30 Chiesi Farmaceutici S.P.A. Liquid propellant-free formulation comprising an antimuscarinic drug
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
JP5959541B2 (ja) 2011-02-25 2016-08-02 ノバルティス アーゲー Ｔｒｋ阻害剤としてのピラゾロ［１，５−ａ］ピリジン
PT2685986T (pt) * 2011-03-18 2020-03-05 Genzyme Corp Inibidor de glicosilceramida-sintase
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
EP2702041A1 (en) * 2011-04-29 2014-03-05 Chiesi Farmaceutici S.p.A. Alkaloid ester and carbamate derivatives and medicinal compositions thereof
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
WO2013038362A1 (en) 2011-09-15 2013-03-21 Novartis Ag 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase
EP2755652B1 (en) 2011-09-16 2021-06-02 Novartis AG N-substituted heterocyclyl carboxamides
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
JP5886433B2 (ja) 2011-09-16 2016-03-16 ノバルティス アーゲー 嚢胞性線維症処置のためのヘテロ環式化合物
EP2793893A4 (en) 2011-11-23 2015-07-08 Intellikine Llc IMPROVED TREATMENT REGIMES USING MTOR INHIBITORS
KR20140105746A (ko) 2011-12-30 2014-09-02 키에시 파르마슈티시 엣스. 피. 에이. 항무스카린제로서 1-아자헤테로시클릴아세트산의 퀴누클리딘 에스터, 이들의 제조 방법 및 이들의 의약 조성물
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
ES2894830T3 (es) 2012-04-03 2022-02-16 Novartis Ag Productos combinados con inhibidores de tirosina·cinasa y su uso
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
WO2014151147A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
WO2015162456A1 (en) 2014-04-24 2015-10-29 Novartis Ag Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
US10004732B2 (en) 2014-04-24 2018-06-26 Novartis Ag Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
MX2016013983A (es) 2014-04-24 2017-04-06 Novartis Ag Derivados de pirazina como inhibidores de fosfatidil-inositol-3-ci nasa.
TW201617342A (zh) 2014-07-11 2016-05-16 阿法馬根公司 調節α７活性之啶類
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
ES2831416T3 (es) 2014-07-31 2021-06-08 Novartis Ag Terapia de combinación de un inhibidor de MET y un inhibidor de EGFR
US9724340B2 (en) 2015-07-31 2017-08-08 Attenua, Inc. Antitussive compositions and methods
JP2022537667A (ja) 2019-06-10 2022-08-29 ノバルティス アーゲー Ｃｆ、ｃｏｐｄ、及び気管支拡張症の治療のためのピリジン及びピラジン誘導体
EP4021572A1 (en) 2019-08-28 2022-07-06 Novartis AG Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
EP4185267A1 (en) 2020-07-24 2023-05-31 Genzyme Corporation Pharmaceutical compositions comprising venglustat

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2762796A (en) 1956-09-11 Iminodibenzyl derivative
GB1219606A (en) 1968-07-15 1971-01-20 Rech S Et D Applic Scient Soge Quinuclidinol derivatives and preparation thereof
GB1246606A (en) 1969-04-28 1971-09-15 Starogardzkie Zakl Farma Dibenzo-azepine derivatives
IL72788A (en) 1984-08-28 1989-07-31 Israel State Bis quaternary oxy-bis methylene(or trimethylene)bis-n-quinuclidines,pyridines and piperidines,their preparation and antidotes against organophosphorus and carbamate poisoning containing them
GB2225574B (en) * 1987-12-24 1991-04-24 Wyeth John & Brother Ltd Heterocyclic compounds
US5066680A (en) * 1989-02-14 1991-11-19 Fujisawa Pharmaceutical Co., Ltd. Novel substituted-acetamide compound and a process for the preparation thereof
GB8923590D0 (en) * 1989-10-19 1989-12-06 Pfizer Ltd Antimuscarinic bronchodilators
GB9119705D0 (en) 1991-09-14 1991-10-30 Pfizer Ltd Therapeutic compounds
GB9201751D0 (en) 1992-01-28 1992-03-11 Smithkline Beecham Plc Compounds
GB9202443D0 (en) 1992-02-05 1992-03-18 Fujisawa Pharmaceutical Co A novel substituted-acetamide compound and a process for the preparation thereof
WO1995021820A1 (fr) * 1994-02-10 1995-08-17 Yamanouchi Pharmaceutical Co., Ltd. Nouveau derive du carbamate et composition correspondante
CN1140447A (zh) * 1994-02-10 1997-01-15 山之内制药株式会社 新的氨基甲酸酯衍生物及其药物组合物
NO2005012I1 (no) * 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
JPH08198751A (ja) * 1995-01-19 1996-08-06 Yamanouchi Pharmaceut Co Ltd カルバメート誘導体
ATE205490T1 (de) 1995-10-13 2001-09-15 Banyu Pharma Co Ltd Substituierte heteroaromatische derivate
AUPN862996A0 (en) 1996-03-13 1996-04-04 Fujisawa Pharmaceutical Co., Ltd. A novel substituted-acetamide compound
PE92198A1 (es) 1996-08-01 1999-01-09 Banyu Pharma Co Ltd Derivados de 1,4-piperidina disustituida que contienen fluor
ES2165768B1 (es) * 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
ATE260277T1 (de) * 2000-06-27 2004-03-15 S A L V A T Lab Sa Von arylalkylaminen abgeleitete carbamate
SK8002003A3 (en) 2000-12-22 2004-05-04 Almirall Prodesfarma Ag Quinuclidine carbamate derivatives and their use as M3 antagonists
AU2002238471B2 (en) 2000-12-28 2007-06-28 Almirall, S.A. Quinuclidine derivatives and their use as M3 antagonists
MXPA04006206A (es) 2001-12-20 2004-12-06 S A L V A T Lab Sa Derivados de 1-alquil-azoniabiciclo(2.2.2(octano carbamato y su uso como antagonistas del receptor musrcarinico.
ES2203327B1 (es) 2002-06-21 2005-06-16 Almirall Prodesfarma, S.A. Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
ES2204295B1 (es) * 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
US6946828B1 (en) * 2003-05-20 2005-09-20 Ami Semiconductor, Inc. Bi-directional current measurement circuit that uses a transconductance amplifier to generate a copy current
ES2246170B1 (es) 2004-07-29 2007-04-01 Almirall Prodesfarma, S.A. Nuevo procedimiento para preparar derivados de carbamato de quinuclidinio.
US20080039494A1 (en) * 2004-12-03 2008-02-14 Jianming Bao 8-Phenyl-5,6,7,8-Hydroquinoline Tachykinin Receptor Antagonists
EP1882691A1 (en) 2006-07-26 2008-01-30 CHIESI FARMACEUTICI S.p.A. Quinuclidine derivatives as M3 antagonists
EP2065385A1 (en) 2007-11-28 2009-06-03 Laboratorios SALVAT, S.A. Stable crystalline salt of (R)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabiciyclo [2.2.2]oct-3-yl ester
EP2080523A1 (en) * 2008-01-15 2009-07-22 CHIESI FARMACEUTICI S.p.A. Compositions comprising an antimuscarinic and a long-acting beta-agonist

Also Published As

Publication number Publication date
ECSP034660A (es) 2003-07-25
US20040242629A1 (en) 2004-12-02
CN1492868A (zh) 2004-04-28
BR0116450A (pt) 2003-09-30
SI1345937T1 (sl) 2006-02-28
NZ526580A (en) 2005-04-29
AR035410A1 (es) 2004-05-26
ZA200304769B (en) 2004-09-20
PL362989A1 (en) 2004-11-15
NO20032889D0 (no) 2003-06-23
JP2004530641A (ja) 2004-10-07
US7776879B2 (en) 2010-08-17
BG107930A (bg) 2004-08-31
ES2248409T3 (es) 2006-03-16
CZ20031758A3 (en) 2004-03-17
RU2296762C2 (ru) 2007-04-10
CA2441896A1 (en) 2002-07-04
NO328707B1 (no) 2010-05-03
US20080021060A1 (en) 2008-01-24
US20040266816A1 (en) 2004-12-30
CZ301323B6 (cs) 2010-01-13
EE200300295A (et) 2003-10-15
HUP0303529A2 (hu) 2004-01-28
PE20020719A1 (es) 2002-10-11
KR100869722B1 (ko) 2008-11-21
DE60113719D1 (de) 2006-02-09
UA76131C2 (en) 2006-07-17
MXPA03005583A (es) 2004-05-05
JP4445704B2 (ja) 2010-04-07
EP1345937B1 (en) 2005-09-28
NO20032889L (no) 2003-08-08
MY136674A (en) 2008-11-28
US7208501B2 (en) 2007-04-24
IL156499A0 (en) 2004-01-04
ATE305468T1 (de) 2005-10-15
HUP0303529A3 (en) 2008-03-28
UY27092A1 (es) 2002-03-22
CN1298717C (zh) 2007-02-07
KR20030067714A (ko) 2003-08-14
EP1345937A1 (en) 2003-09-24
HK1055120A1 (en) 2003-12-24
WO2002051841A1 (en) 2002-07-04
SK8002003A3 (en) 2004-05-04
US7312231B2 (en) 2007-12-25
DE60113719T2 (de) 2006-09-28
AU2002228015B2 (en) 2007-08-23

Similar Documents

Publication Publication Date Title
DK1345937T3 (da) Quinuclidincarbamatderivater og deres anvendelse som M3-antagonister
DK1498413T3 (da) 4-aminopicolinater og deres anvendelse som herbicider
DK1478629T3 (da) N-aryl-2-oxazolidinon-5-carboxamider og deres derivater og deres anvendelse som antibakterielle midler
NO20025357L (no) Antranylamider og deres anvendelse som legemidler
NO20021253L (no) Kinolylpropylpiperidinderivater og deres anvendelse som antibakterielle midler
NO20026010D0 (no) Substituerte quinazolinderivater og deres anvendelse som inhibitorer
NO20014135L (no) Nye sulfonamidforbindelser og deres anvendelse
NO20032277D0 (no) Aminotiazoler og deres anvendelse som adenosinreseptorantagonister
NO20024742D0 (no) Heterocykliske forbindelser, deres fremstilling og anvendelse
NO20020383D0 (no) Mutilinderivater og deres anvendelse som anti-bakterielle midler
NO20033565D0 (no) Acylerte indanylaminer og deres anvendelse som farmasöytiske midler
DK1394150T3 (da) 4-phenylpyridinderivater og deres anvendelse som NK-1-receptorantagonister
DK1200431T3 (da) Quinuclidinderivater og deres anvendelse som muskarine M3-receptorligander
NO20030298D0 (no) Nye heteroarylderivater og deres anvendelse som farmasöytiske midler
NO20014603L (no) Tienopyrimidinforbindelser, deres fremstilling og anvendelse
NO20030471D0 (no) Karboksamidforbindelser og deres anvendelse som antagonister for en 11CBY-reseptor
NO20053569L (no) Substituerte 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazinderivater og deres anvendelse som nevrokininantagonister
DK1170288T3 (da) Diphenylurinstofderivater og deres anvendelse som alfa2/5-HT2c-antagonister
NO20025150L (no) 2-acylindolderivater og deres anvendelse som antitumormidler
NO20031838D0 (no) Benzokazinonderivater, deres fremstilling og anvendelse
DK1387838T3 (da) Cyanoanthranylamid-derivater og deres anvendelse som lægemidler
DK1265892T3 (da) Isothiazolderivater og deres anvendelse som pesticider
NO20030547D0 (no) Azabicykliske derivater og deres terapeutiske anvendelse
DK1259515T3 (da) Thienopyridinderivater og deres anvendelse som antiinflammatoriske midler
DK1200409T3 (da) Substituerede isoquinolinderivater og deres anvendelse som krampestillende midler